Last reviewed · How we verify
ALXN1720 SC
ALXN1720 SC is a Small molecule drug developed by Alexion Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | ALXN1720 SC |
|---|---|
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis (PHASE3)
- PK Study of Gefurulimab SC in Healthy Chinese Adult Participants (PHASE1)
- A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants (PHASE1)
- Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria (PHASE1)
- Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALXN1720 SC CI brief — competitive landscape report
- ALXN1720 SC updates RSS · CI watch RSS
- Alexion Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ALXN1720 SC
What is ALXN1720 SC?
ALXN1720 SC is a Small molecule drug developed by Alexion Pharmaceuticals, Inc..
Who makes ALXN1720 SC?
ALXN1720 SC is developed by Alexion Pharmaceuticals, Inc. (see full Alexion Pharmaceuticals, Inc. pipeline at /company/alexion-pharmaceuticals-inc).
What development phase is ALXN1720 SC in?
ALXN1720 SC is in Phase 1.
Related
- Manufacturer: Alexion Pharmaceuticals, Inc. — full pipeline
- Compare: ALXN1720 SC vs similar drugs
- Pricing: ALXN1720 SC cost, discount & access